Identification of CXCR4 and CXCL10 as Potential Predictive Biomarkers in Triple Negative Breast Cancer (TNBC)

AC 1 Tian Chuan*
CE 2 Tian Li*
BCE 3 Cui Yi

* Tian Chuan and Tian Li contributed equally to this work
Corresponding Author: Cui Yi, e-mail: anniecui0808@163.com
Source of support: Departmental sources

Background: Efficacious therapy for triple negative breast cancer (TNBC) continues to be a profound clinical challenge, but the key driven genes and convoluted signaling pathways are still unknown.

Material/Methods: A total of 223 samples (163 TNBC and 60 healthy breast tissues) were taken and deeply integrated analyzed by R software from 4 expression profiles in the study, including GSE53752, GSE45827, GSE65194, and GSE38959. We examined differentially expressed genes (DEGs) and screen for critical genes and pathways enrichment. The protein-protein interaction (PPI) network of DEGs-associated was built through the STRING Version: 11.0 database and Cytoscape software to filter the hub gene. Then, we verified hug gene expression levels through the Oncomine database. Also, we analyzed the prognostic value of TNBC patient’s hub genes using the Kaplan-Meier plotter database.

Results: In our study, we filter out 365 DEGs, including 212 upregulated genes and 153 downregulated genes. Then, 10 hub genes were picked out by the intersection of 12 algorithms. At the same time, we discovered that CXCR4 and CXCL10 overexpression are favorable prognostic factors for recurrence-free survival of TNBC through the Kaplan-Meier plotter database.

Conclusions: Our research found that CXCR4 and CXCL10 overexpressed, and they were a favorable prognostic factor in patients with TNBC. CXCR4 and CXCL10 might be effective targets for TNBC therapy.

MeSH Keywords: Chemokine CXCL10 • Genes, abl • Receptors, CXCR4

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/918281
Background

Triple negative breast cancer (TNBC) is a common type of breast cancer (BC), which lacks expression of the estrogen, progesterone and human epidermal growth factor receptor 2 [1]. This subtype represents 12% to 17% of the breast cancers [2]. It often occurs in young women [3], and it is more likely to recurrence and metastasize [4]. As this subtype lacks molecular targets, patients with TNBC cannot be treated with human epidermal growth factor receptor 2 (HER2)-targeted therapy or endocrine therapy. Currently, chemotherapy is the primary treatment for patients with TNBC [5]. Unfortunately, many tumors have significant drug resistance, and rapid recurrence and metastasis after neoadjuvant chemotherapy [6]. As of now, TNBC still has very limited treatment options and poor prognosis [7]. Therefore, it is necessary to further explore the potential therapeutic genes and novel targets of TNBC.

For the TNBC, we re-analyzed the gene expression profiles of GSE45827 [8], GSE65194 [9–11], GSE53752 [12] and GSE38959 [13] and determined the differentially expressed genes (DEGs) in 163 TNBC and 60 normal breast tissues samples. Bioinformatics analysis was used for functional enrichment analysis of DEGs, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). Next, we constructed a protein-protein interaction (PPI) network to filter hub genes related to TNBC and validation of hub gene expression levels by the Oncomine database. We performed a survival analysis of the hub gene by the Kaplan-Meier plotter database. We defined the DEGs, and enriched the biological functions and candidate genes, to provide new biomarkers of TNBC patients for early diagnosis and treatment.

Material and Methods

Data source

Data sets of our study were all from the Gene Expression Omnibus (GEO) public database (https://www.ncbi.nlm.nih.gov/geo/) and 4 sets of gene expression profiling chips (GEPC) are selected, including GSE38959 (GPL4133; Agilent-014850 Whole Human Genome Microarray 4 x 44 K G4112F), GSE53752 (GPL7264; Agilent-012097 Human 1A Microarray (V2) G4110B), GSE45827 and GSE65194 (GPL570; [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array).

Differentially expressed genes (DEGs)

The robust multi-array average (RMA) approach performed for background correction and normalization. The original GEO data were then converted into expression measures using the affy R package. Limma R package was subsequently employed for identifying differentially expressed genes (DEGs). We use \( P<0.05 \) and \(|\log FC| >1\) as data processing standards for analysis. We analyzed each data set and cross-screened differentially expressed genes using Venn 2.1 webtool (http://bioin-fog.cnb.csic.es/tools/venny/index.html).

Table 1. Top 10 hub genes by intersection of 12 algorithms.

| Gene symbol | Gene description | Algorithms | Probe ID |
|-------------|------------------|------------|----------|
| MKI67       | Marker of Proliferation Ki-67 | MCC, MNC, Degree, EPC, BottleNeck, Eccentricity, Closeness, Radiality, Betweenness, Stress | 212023_at |
| FOXM1       | Forkhead Box M1 | MCC, MNC, Degree, EPC, Eccentricity, Closeness, Radiality, Betweenness, Stress | 202580_at |
| GAPDH       | Glyceraldehyde-3-Phosphate Dehydrogenase | MNC, Degree, EPC, BottleNeck, Eccentricity, Closeness, Radiality, Betweenness, Stress | 212581_at |
| KIT         | KIT Proto-Oncogene Receptor Tyrosine Kinase | MNC, Degree, EPC, BottleNeck, Closeness, Radiality, Betweenness, Stress | 205051_at |
| IGF1        | Insulin Like Growth Factor 1 | MNC, Degree, EPC, Closeness, Radiality, Betweenness, Stress | 209541_at |
| CCNB2       | Cyclin B2 | MCC, Degree, EPC, BottleNeck, Eccentricity, Stress | 202705_at |
| CDKN2A      | Cyclin Dependent Kinase Inhibitor 2A | BottleNeck, Eccentricity, Closeness, Radiality, Betweenness, Stress | 207039_at |
| CXCR4       | C-X-C Motif Chemokine Receptor 4 | MNC, Degree, EPC, Closeness, Radiality, Stress | 217028_at |
| ICAM1       | Intercellular Adhesion Molecule 1 | MNC, Degree, EPC, BottleNeck, Closeness, Radiality | 202638_at |
| CXCL10      | C-X-C Motif Chemokine Ligand 10 | MNC, Degree, EPC, Betweenness | 204533_at |
Enrichment analysis

GO function enrichment analysis consists of 3 parts, namely the biological process (BP), molecular function (MF) and cellular component (CC). KEGG is a database for storing genomic and biological pathways. In this study, we performed GO function and KEGG pathway enrichment analysis of DEGs by DAVID 6.7 database tool (https://david.ncifcrf.gov/). The P-value of <0.05 to be considered statistically significant.

PPI and hub gene

We analyze the PPI network of DEGs through the STRING v11.0 database (https://string-db.org/cgi/input.pl?sessionId=JUci4htYBrbs and input_page_active_form=multiple_identifiers), which select score >0.4 to extract PPIs for DEGs. Then, visualize the PPI network with Cytoscape v3.7.1 software. Nodes with higher connectivity degree are more likely to maintain overall network stability. Next, we use the cytoHubba to calculate the degree of each protein node. In this study, we identified 10 hub genes by 12 algorithms (Maximal Clique Centrality (MCC), Density of Maximum Neighborhood Component (DMNC),...
Table 3. The 365 Differentially Expressed Genes (DEGs) were identified from 4 profile datasets, including 212 upregulated and 153 downregulated genes in the Triple-Negative Breast Cancer (TNBC) tissues compared to normal breast tissues.

| DEGs | Genes name |
|------|------------|
| Upregulated | CXCR4, IRAK1, GPSM2, CCNB1, CAPS, CCNE1, FOXM1, OR3A, EN1, TTL4, GNB4, KIF14, MAD2L1, TTC13, KIF4A, SQA, MCM10, TYMS, MELK, HN1, NDC80, OIP5, CCNA2, HARSLS, MMP1, STMN1, CKS2, DEPC1, BR3BP, IDO1, LMBN1, SPA5G, CCNB2, PRC1, LRP8, CCNE2, MCM4, WISP1, CXL10, Ckap2, SULF1, CDC2A, RPP25, EXO1, HPSE, KDEL2R, COL11A1, HST11H1, HORMAD1, NEK2, TME2406, BAIAP2L1, C1orf106, ATP6V0B, EZH2, CHEK1, KIF11, TAP1, KIF1C, MASTL, VGLL1, ARTN2L, HIST2H2AA4, RRS1, PYCR1, KCNK1, CENPA, RNF12, CDC7A, CENP N, FAM3A, FAM5H, RAP1A, CDCA8, TPX2, ANP32E, KPNA2, AMLN, BIRC5, LAMP3, KLRG2, RACGAP1, ESR, CDC6, APOBEC3B, AURKA, FN1, AURKB, CSTB, FANCA, TMEM79, SPPL, IL4I1, IMPA2, USP18, RHDC, ZWINT, GTF2, U2F1, PTTG1, CDC5, UBE2T, BCL2A1, RNG1, TEAD4, PPP1CA, ECT2, MMP11, MYB1L, GGH, HMOX1, PARP12, PPP1R14B, TACC3, LCECA7A, DCD1L1, CEP15, GZMB, MFAP2, DQAGPS, RAD51AP1, TBC1D7, MKI67, TME2413C, IL32, LZ7, NMU, GAPDH, SLC39A1, KIAA0100, HSD17B6, GINS2, PANSON, E2F8, TSTAS3, S100P, HMGB1, HOMER3, FLCRN1, SLC9A7, C16orf59, ADAMDEC1, TMEM45A, IDH2, CXL11, STK38L, OAS3, ZIC1, BLM, KIF2C, CCNYL1, KIF20A, SOX11, P4HB, CHAC2, TCK, NCGAP, NUSAP1 |
| Downregulated | KLHL13, IGF1, PPP1R14A, NAP1L2, AURKA, FN1, AURKB, CSTB, FANCA, TMEM79, SPPL, IL4I1, IMPA2, USP18, DHCR, ZWINT, GTF2, U2F1, PTTG1, CDC5, UBE2T, BCL2A1, RNG1, TEAD4, PPP1CA, ECT2, MMP11, MYB1L, GGH, HMOX1, PARP12, PPP1R14B, TACC3, LCECA7A, DCD1L1, CEP15, GZMB, MFAP2, DQAGPS, RAD51AP1, TBC1D7, MKI67, TME2413C, IL32, LZ7, NMU, GAPDH, SLC39A1, KIAA0100, HSD17B6, GINS2, PANSON, E2F8, TSTAS3, S100P, HMGB1, HOMER3, FLCRN1, SLC9A7, C16orf59, ADAMDEC1, TMEM45A, IDH2, CXL11, STK38L, OAS3, ZIC1, BLM, KIF2C, CCNYL1, KIF20A, SOX11, P4HB, CHAC2, TCK, NCGAP, NUSAP1 |

Maximum Neighborhood Component (MNC), Degree, Edge Percolated Component (EPC), Bottleneck (BN), Eccentricity, Closeness, Radiality, Betweenness, Stress, Clustering Coefficient). Then, Oncomine was utilized to investigate hub gene expression of breast cancer in multiple datasets.

**ONCOMINE analysis**

ONCOMINE is a publicly available genome-wide online cancer microarray database (https://www.oncomine.org/resource/login. html). In our study, we generated a P-value by Student’s t-test in the TNBC group compared with the normal control group, which fold change was 2 and P-value was 0.01.

**Survival analysis**

In this study, overall survival and relapse-free survival rate was analyzed using samples from 1402 breast cancer patients and 3955 TNBC patients. We used the Kaplan-Meier plotter database (http://kmplot.com/analysis/index.php?p=service&cancer=breast) to assess the prognostic value of BC hub genes, especially in TNBC with estrogen (ER), progesterone (PR) and HER2 negative expression patients. Based on the only Jetset best probe set and the probe IDs for each gene are shown in Table 1. Then, we divided the median values of each gene in each patient of TNBC into the 2 groups. P-value of <0.05 was considered statistically significant.

**Results**

**Differentially expressed genes**

In this study, we selected 4 GEPC (GSE45827, GSE53752, GSE38959, and GSE65194) from the GEO database. GSE45827 and GSE65194 included 41 TNBC and 11 healthy breast samples, GSE53752 contained 51 TNBC samples and 25 healthy breast samples and GSE38959 contained 30 TNBC and 13 healthy breast samples (Table 2). Volcano plots were generated to visualize the distribution of expressed genes between breast cancer and normal controls from different studies. Red or green dots in the plots represented significantly upregulated or downregulated genes respectively. Using the P<0.05 and |logFC| >1 as cutoff criterion, we recovered 4760, 3919, 1335,
and 2791 the DEGs from GEO database GSE45827, GSE65194, GSE53752, and GSE38959 (Figure 1A–1D). Then, we screened 365 differentially expressed genes from 4 data sets through bioinformatics compared to normal breast tissues in the TNBC tissues (Figure 1E), including 153 downregulated genes and 212 upregulated genes (Table 3).

**Functional enrichment analyses**

We used the DAVID online tool to perform GO and KEGG functional analysis of DEGs (Table 4). Functional enrichments of genes with FDR <0.05 were obtained. GO enrichment analysis is divided into BP, CC, and MF, including mitotic nuclear division, cell division, sister chromatid cohesion, chromosome segregation, mitotic sister chromatid segregation, DNA replication, mitotic metaphase plate congression, mitotic cytokinesis, G1/S transition of mitotic cell cycle, mitotic spindle organization, positive regulation of cell proliferation, spindle organization; midbody, condensed chromosome kinetochore, chromosome centromeric region, kinetochore, spindle, spindle pole, extracellular space, nucleus, spindle microtubule, spindle midzone; microtubule motor activity, protein binding.

| Category   | Term                        | Description                                      | Count | FDR          |
|------------|-----------------------------|--------------------------------------------------|-------|--------------|
| BP Term    | GO: 0051301                 | Cell division                                    | 38    | 9.09348E-14 |
| BP Term    | GO: 0007067                 | Mitotic nuclear division                          | 32    | 3.88578E-13 |
| BP Term    | GO: 0007062                 | Sister chromatid cohesion                        | 17    | 2.9882E-07  |
| BP Term    | GO: 0007059                 | Chromosome segregation                            | 13    | 1.32402E-05 |
| BP Term    | GO: 0006260                 | DNA replication                                   | 16    | 0.000750953 |
| BP Term    | GO: 0007080                 | Mitotic metaphase plate congression               | 9     | 0.000851431 |
| BP Term    | GO: 0000082                 | G1/S transition of mitotic cell cycle            | 13    | 0.001349094 |
| BP Term    | GO: 0000281                 | Mitotic cytokinesis                               | 8     | 0.002021202 |
| BP Term    | GO: 0007052                 | Mitotic spindle organization                      | 8     | 0.002592039 |
| BP Term    | GO: 0008283                 | Cell proliferation                                | 23    | 0.006602397 |
| BP Term    | GO: 0008284                 | Positive regulation of cell proliferation        | 26    | 0.010896295 |
| BP Term    | GO: 0007051                 | Spindle organization                              | 6     | 0.018277854 |
| CC Term    | GO: 0030496                 | Midbody                                          | 17    | 6.28264E-06 |
| CC Term    | GO: 0000775                 | Chromosome, centromeric region                    | 12    | 1.52009E-05 |
| CC Term    | GO: 0000777                 | Condensed chromosome kinetochore                 | 14    | 1.83106E-05 |
| CC Term    | GO: 0000776                 | Kinetochore                                      | 12    | 0.000657356 |
| CC Term    | GO: 0005819                 | Spindle                                          | 14    | 0.000966442 |
| CC Term    | GO: 000922                  | Spindle pole                                     | 13    | 0.001994984 |
| CC Term    | GO: 0005615                 | Extracellular space                              | 53    | 0.002367057 |
| CC Term    | GO: 0005634                 | Nucleus                                          | 144   | 0.018757183 |
| CC Term    | GO: 0005876                 | Spindle microtubule                               | 8     | 0.028575601 |
| CC Term    | GO: 0051233                 | Spindle midzone                                  | 6     | 0.034840011 |
| MF Term    | GO: 0005515                 | Protein binding                                  | 214   | 0.015739274 |
| MF Term    | GO: 003777                  | Microtubule motor activity                       | 10    | 0.041584748 |
| KEGG PATHWAY | hsa04110                   | Cell cycle                                       | 15    | 0.00066844 |
| KEGG PATHWAY | hsa04114                   | Oocyte meiosis                                   | 13    | 0.00711138  |

**Table 4.** Significantly enriched GO terms and KEGG pathways of DEGs.

BP – biological process; CC – cellular component; DEG – differentially expressed gene; ECM – extracellular matrix; GO – Gene Ontology; KEGG – Kyoto Encyclopedia of Genes and Genomes.
In addition, we found that KEGG pathway analysis of DEGs is mainly enriched in oocyte meiosis and cell cycle. The results are shown in Figure 2.

**PPI and hub gene**

We enter the DEGs into STRING Version: 11.0 database to forecast PPI, and then the date of PPI network was refined using Cytoscape. After removing the isolated and partially connected nodes, the complex network of DEGs was established in Figure 3A. Evaluation of the top 10 genes by intersection of 12 algorithms with PPI networks (Table 1, Figure 3B–3M). The results showed that the expression of MKI67, FOXM1, GAPDH, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10 had marked differences among different datasets in BC (Figure 4).

**ONCOMINE analysis of hub genes**

To detect the expression of hub genes, we researched that revealed hub genes mRNA expression levels of BC were significantly higher than healthy tissue samples by Oncomine analysis datasets of different cancer types (Figure 5).

**Survival analysis**

We evaluated hub genes using the Kaplan-Meier plotter tool for analysis of overall survival and relapse-free survival in 1402 BC patients. Simultaneously, we detected that high expression of KIT, IGF1 ICAM1, low expression of MKI67, FOXM1, GAPDH, and CCNB2 hub gene contributes to overall survival in BC patients. However, no significant difference was found in the CDKN2A, CXCR4, and CXCL10 of hub genes for overall survival analysis (Figure 6).

However, only overexpression of CXCR4 (hazard ratio [HR]=0.6; 95% confidence interval [CI]: 0.39–0.93; P=0.02; n=386) and CXCL10 (HR=0.43; 95% CI: 0.28–0.68; P=0.00016; n=386) were the favorable prognostic factors related to relapse-free survival in TNBC patients. The results are shown in Figure 7.
Figure 3. (A–M) Protein-protein interaction network and top 10 hub genes. Red node indicates the upregulated gene and green node indicates the downregulated gene.
Figure 4. Meta-analysis of differentially expressed hub genes. Meta-analysis of MKI67, FOXM1, GAPDH, KIT, IGF1, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10 gene expressions in TNBC and normal tissue shows that they are significantly differentially expressed. Statistical analysis was performed using the Oncomine gene expression database. The heat maps represent the relative expression in patients with the indicated TNBC compared with normal tissue. Red indicates overexpression in TNBC patients and blue indicates under expression. The reported median ranks and p values consider all indicated studies simultaneously. TNBC = triple-negative breast cancer.

Figure 5. The mRNA expression pattern of hub genes in different tumor types. mRNA expression upregulated (red), downregulated (blue). The p value threshold is 0.01.
TNBC is the primary subtype of BC with poor prognosis and lack of valid therapeutic targets. Because of the lack of useful therapeutic targets, TNBC patients cannot benefit from endocrine therapy or HER2 targeted therapy, so chemotherapy is the primary adjunct therapy. However, TNBC patients are more susceptible to drug resistance. So, it is necessary to find new specific targets for TNBC patients.

Based on public databases for gene expression and PPI analysis, we identified potential critical genes associated with TNBC. Then, we screened DEGs with normal breast tissue from the GEO database. Among them, we screened 212 upregulated...
genes and 153 downregulated DEGs associated with GO terms including cell division, mitotic nuclear division, extracellular space, nucleus, midbody, protein binding, and microtubule motor activity, and mainly enriched in the KEGG terms cell cycle and oocyte meiosis. We constructed the PPI network using differentially expressed genes and screened 10 hub genes by the intersection of 12 algorithms, including MKI67, FOXM1, GAPDH, KIT, IGF1, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10. Among MKI67, FOXM1, GAPDH, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10 were significantly upregulated in TNBC. Finally, we used the Kaplan-Meier plotter tool to predict the prognosis of hub genes in patients with TNBC.

Through the Kaplan-Meier plotter online public tool, overexpression of MKI67, FOXM1, GAPDH, and CCNB2 were associated with unfavorable prognosis in BC patients, no significant difference was found in the CDKN2A, CXCR4, and CXCL10 of hub genes for overall survival analysis (Figure 6). We found that overexpression of CXCR4 and CXCL10 were related to the favorable prognostic factor of TNBC patients (Figure 7).

CXCR4, CXC motif chemokine receptor type 4, is involved in either normal (maintaining stemness [14] or induced differentiation [15]) or abnormal (developing cancer [16] and other pathologies [17]) events. CXCL10, CXC motif chemokine ligand 10, may accelerate cancer growth in nonimmune cell types and orchestrate an antitumor response [18]. CXCR4 has been associated with several diseases, including human immunodeficiency virus (HIV) infection [19], cancers [17], and warts, hypogammaglobulinemia, immunodeficiency, myelokathexis (WHIM) syndrome [20]. Some research has demonstrated that CXCR4 can be developed to treat these diseases, especially related to the prognosis of cancers such as colorectal cancer [21,22], thyroid carcinoma [23], head and neck squamous cell carcinomas [24], and breast cancer [25]. It was reported that the inhibitors of CXCR4 could benefit to TNBC patients [26], but some reports showed that it could not benefit to triple-negative breast cancer patients [27]. Thus, the role of CXCR4 needs further study.

It has been reported that CXCL10 might be related to the prognosis in pancreatic adenocarcinoma [28] and TNBC [29]. Our research showed that CXCR4 and CXCL10 overexpression could be related to the prognosis of malignant diseases. For TNBC, our studies demonstrated that CXCR4 and CXCL10 were the chemokines related to prognosis. Therefore, CXCR4 and CXCL10 might be an effective prognostic factor and obviously potential therapeutic target for TNBC treatment.

In addition to CXCR4 and CXCL10, the remaining 8 hub genes were the MKI67, FOXM1, GAPDH, KIT, IGF1, CCNB2, CDKN2A, and ICAM1. We found that these genes had no significant difference for TNBC analysis. This result was consistent with the Oncomine database. However, the mechanism of these hub genes is not fully understood in TNBC and needs further study.

**Conclusions**

Bioinformatics identified 365 differentially expressed genes from the GEO database. Among them, TNBC-related 10 hub genes including MKI67, FOXM1, GAPDH, KIT, IGF1, CCNB2, CDKN2A, CXCR4, ICAM1, and CXCL10. All of them upregulated in TNBC except for KIT and IGF1. We found that overexpression of CXCR4 and CXCL10 were the favorable prognostic factor in relapse-free survival in TNBC.

|Gene| GEO Accession| Expression| Number at risk| HR| logrank P|
|---|---|---|---|---|---|
|CXCR4| 217028_at| low| 128| 127| 0.6 (0.39–0.93) | 0.02|
|CXCL10| 204533_at| low| 128| 127| 0.43 (0.28–0.68) | 0.00016|

**Figure 7.** (A, B) Kaplan-Meier plotter online tool for detecting relapse-free survival of CXCR4 and CXCL10 in triple-negative breast cancer.
These results show that it is necessary to explore the clinical treatment value of CXCR4 and CXCL10 in TNBC, as they might be the possible target for TNBC treatment.

References:

1. Garrido-Castro AC, Lin NJ, Polyak K: Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment. Cancer Discov, 2019; 9(2): 176–98
2. Shi J, Kobayashi LC, Grundy A et al: Lifetime moderate-to-vigorous physical activity and ER/PR/HER-defined post-menopausal breast cancer risk. Breast Cancer Res, Treat, 2017; 165(3): 203–13
3. Villarreal-Garza C, Bargallo-Rocha IFE, Soto-Perez-de-Celis E et al: Real-world outcomes in young women with breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat, 2016; 157(2): 385–94
4. El Ayachi I, Fatima L, Wend P et al: The WNT10B network is associated with survival and metastases in chemo-resistant triple-negative breast cancer. Cancer Res, 2019; 79(5): 982–93
5. Heiser LM, Baldeyron C, Richardson M et al: TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One, 2013; 8(5): e63712
6. Guo P, Yang J, Liu D et al: Dual complementary liposomes inhibit triple-negative breast cancer cells. PLoS One, 2015; 10(4): e0122333
7. Maire V, Némati F, Richardson M et al: Polo-like kinase 1: A potential therapeutic target for triple-negative breast cancer. Expert Opin Investig Drugs, 2019; 28(1): 1–5
8. Gruosso T, Mieulet V, Cardon M et al: Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med, 2016; 8(5): 527–43
9. Maubant S, Tessonn B, Maire V et al: Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. PLoS One, 2015; 10(6): e0122333
10. Maire V, Baldeyron C, Richardson M et al: TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS One, 2013; 8(5): e63712
11. Maire V, Némati F, Richardson M et al: Polo-like kinase 1: A potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res, 2013; 73(2): 813–23
12. Kuo WH, Chang YY, Lai LC et al: Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: A clinical study of triple-negative breast carcinomas. PLoS One, 2012; 7(9): e45831
13. Komatsu M, Yoshimaru T, Matsuo T et al: Molecular features of triple-negative breast cancer cells by genome-wide gene expression profiling analysis. Int J Oncol, 2013; 42(2): 478–506
14. Kawaguchi N, Zhang TT, Nakanishi T: Involvement of CXCR4 in normal and abnormal development. Cells, 2019; 8(2): pii: E185
15. Green MM, Chao N, Chhabra S et al: Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. J Hematol Oncol, 2016; 9(1): 71
16. Tulotta C, Stefanescu C, Chen Q et al: CXCR4 signaling regulates metastatic onset by controlling neutrophil motility and response to malignant cells. Sci Rep, 2019; 9(1): 2399
17. Seo YD, Jiang X, Sullivan KM et al: Mobilization of CD8+ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer. Clin Cancer Res, 2019; 25(13): 3934–45
18. Brownell J, Polyak S: Molecular pathways: Hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res, 2013; 19(6): 1347–52
19. Gupta RK, Abdul-Jawad S, McCoy LE et al: HIV-1 remission following CCR5a32/A32 haematopoietic stem-cell transplantation. Nature, 2019; 68(7751): 244–48
20. Heiser LM, Mills GB, Gray JW: Therapeutic clues from an integrated OMIC assessment of east Asian triple negative breast cancers. Cancer Cell, 2019; 35(3): 341–43
21. Cabrero-de LasHeras S, Martinez-Balibrea E: CXCR4 family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol, 2018; 24(42): 4738–49
22. Xu C, Zheng L, Li D et al: CXCR4 overexpression is correlated with poor prognosis in colorectal cancer. Life Sci, 2018; 208: 333–40
23. Werner TA, Forster CM, Dizdar L et al: CXCR4/CXCR7/CXCL12 axis promotes an invasive phenotype in medullary thyroid carcinoma. Br J Cancer, 2017; 117(12): 1837–44
24. De-Colle C, Menegakis A, Mönnich D et al., DKTK-ROG: SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiother Oncol, 2018; 126(1): 125–31
25. Xu L, Cheng L, Yang F et al: JWA suppresses the invasion of human breast carcinoma cells by downregulating the expression of CXCR4. Mol Med Rep, 2018; 17(6): 8137–44
26. Xiong L, Hurchla MA, Fontana F et al: CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer. Mol Cancer Ther, 2015; 14(11): 2473–85
27. Lefort D, Thuleau A, Kieffer Y et al: CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene, 2017; 36(9): 1211–22
28. Qian L, Yu S, Yin C et al: Plasma IFN-γ correlates with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Panreatology, 2019; 19(2): 340–45
29. Adams S, Diamond JR, Hamilton E et al: Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: A phase 1b clinical trial. JAMA Oncol, 2019; 5(3): 334–42

Conflicts of interest

None.